Table 2.

Comparative analysis of key clinical and immunological variables in suspected PID versus SID within NHL patients

Variable	“PID-suspected NHL group” No. = 52	“SID NHL Group” No. = 13	P-value
Childhood recurrent&severe infections	21 (40.4%)	0 (0%)	0.005
Infections prior to NHL diagnosis	23 (44.2%)	1 (7.7%)	0.01
Infections after NHL diagnosis	30 (57.7%)	4 (30.8%)	0.08
Malabsorptive syndrome	17 (32.7%)	2 (15.4%)	0.22
Second primary neoplasia	15 (28.8%)	2 (15.4%)	0.32
Family history of B cell neoplasms	8 (15.4%)	0 (0%)	0.13
Serum IgM at NHL diagnosis (mg/dL)	56.12 ± 44.54 40	225.23 ± 19.79 56	< 0.0001
Sum kappa + lambda (mg/dL)	23.48 ± 15.06 15	33.00 ± 12.00 23	0.03
Class-switched memory B cells (%)	2.06 ± 5.29 0	6.33 ± 2.12 9	0.006

The data are presented as the number of patients (percentage). For laboratory values, the data are expressed as mean ± standard deviation (SD) and median